Table 8.
Serum C3, C4, and plasma FH + FHL1 levels evaluated at the time of anti-FH measurement.
| Patient ID | Biochemical complement parameters | ||||
|---|---|---|---|---|---|
| Disease phase | Anti-FH titer (AU/mL) | C3 level (90–180 mg/mL) | C4 level (10–40 mg/mL) | FH+FHL1 level (172–507 mg/L) | |
| 1 | Rem | 453.4 | 30 | 12 | na |
| 2 | Rem | 381.6 | 141 | 27 | na |
| 3 | Rem | 280.8 | 112 | 29 | na |
| 4 | Rem | 513.2 | na | na | na |
| 5 | Rem | 146.6 | 85 | 25 | 349 |
| 6 | Rem | 243.0 | 81 | 26 | 309 |
| 7 | Rem | 572.0 | 94 | 17 | 312 |
| 8 | Rem | 1,646.1 | 77 | 31 | 283 |
| 9 | Rem | 876.7 | 70 | 19 | 302 |
| 10 | Acute | 1,314.9 | 103 | 25 | 397 |
| 11 | Acute | 2,781.0 | 96 | 28 | na |
| 12 | Rem | 342.9 | 185 | 62 | 307 |
| 13 | Rem | 1,590.4 | 118 | 22 | 686 |
| 14 | Rem | 1,557.3 | 35 | 27 | 80 |
| 15 | Rem | 862.3 | 100 | 30 | 438 |
| 16 | Rem | 877.4 | na | na | 308 |
| 17 | Rem | 189.15 | 106 | 70 | 446 |
| 18 | Rem | 531.2 | 75 | 14 | 463 |
| 19 | Rem | 226.6 | 78 | 20 | 374 |
| 20 | Rem | 111.8 | 149 | 38 | 432 |
| 21 | Rem | 96.6 | 39 | 25 | 244 |
| 22 | Rem | 102.1 | 89 | 39 | 362 |
| 23 | Acute | 123.1 | 54 | 29 | 307 |
| 24 | Rem | 77.6 | 126 | 35 | 226 |
| 25 | Acute | 440.15 | 95 | 27 | 317 |
| 26 | Rem | 141.2 | 96 | 27 | 362 |
| 27 | Rem | 65.2 | 65 | 14 | 246 |
| 28 | Rem | 57.1 | 99 | 22 | 372 |
| 29 | Rem | 303.9 | 68 | 11 | na |
| 30 | Rem | 1,321.7 | 63 | 31 | 337 |
| Mean ± SD | Mean ± SD | Mean ± SD | Mean ± SD | ||
| Acute (n = 4) | 1,164.8 ± 1,189.5 | 87 ± 22.3 | 27.2 ± 1.7 | 340.3 ± 49.3 | |
| Rem (n = 26) | 521.8 ± 504.3 | 90.9 ± 36.3 | 28 ± 14 | 344.7 ± 117.1 | |
The phase of the disease when the samples were collected (Rem, remission phase; Acute, acute phase), the anti-FH titer, and serum C3, C4 levels and plasma FH + FHL1 levels are shown. Normal ranges are in brackets; na, not available.